Keywords: immunomedics, epratuzumab, distinct, rituxan, nasdaq-listed, therapeutic, monoclonal
Immunomedics' epratuzumab "distinct from Rituxan"
Article | 20 November 2006
Nasdaq-listed therapeutic monoclonal antibody specialist Immunomedics has reported study data indicating that its lead drug candidate epratuzumab has a distinct ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
